1. Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: A case report
- Author
-
Anne Minello, Georges Mantion, Fabrice Larosa, Gaël Piton, Patrick Hillon, Becker Mc, Vincent Di Martino, Eric Deconinck, and François Aubin
- Subjects
Transplantation ,Hepatology ,business.industry ,medicine.medical_treatment ,chemical and pharmacologic phenomena ,Disease ,Hematopoietic stem cell transplantation ,030230 surgery ,Liver transplantation ,Pathophysiology ,Infliximab ,3. Good health ,03 medical and health sciences ,surgical procedures, operative ,0302 clinical medicine ,Cytokine ,Refractory ,immune system diseases ,Immunology ,medicine ,030211 gastroenterology & hepatology ,Surgery ,Tumor necrosis factor alpha ,business ,medicine.drug - Abstract
Acute graft-versus-host disease (GVHD) following orthotopic liver transplantation is a rare but severe disease with a 75% death rate in adults. Various therapeutic strategies have been proposed for steroid-refractory GVHD, but there is still no consensus. Tumor necrosis factor-alpha is a key inflammatory cytokine involved in acute GVHD physiopathology, and infliximab has shown encouraging results for the treatment of acute GVHD following hematopoietic stem cell transplantation. We report the first case of acute GVHD following liver transplantation that was refractory to steroids and anti-lymphocyte globulin but was successfully treated with infliximab.
- Published
- 2009